Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Gastrointestinal Stromal Tumors 71Leukemia 69Leukemia, Myeloid, Chronic-Phase 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Blast Crisis 22Neoplasms 15Brain Neoplasms 15Philadelphia Chromosome 14Melanoma 13Sarcoma 12Neoplasm Metastasis 12Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Glioblastoma 12Lung Neoplasms 11Prostatic Neoplasms 10Leukemia, Myeloid 9Gliosarcoma 9Glioma 8Breast Neoplasms 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Central Nervous System Neoplasms 7Astrocytoma 7Recurrence 6Polycythemia Vera 6Ovarian Neoplasms 6Oligodendroglioma 6Myeloproliferative Disorders 6

Interventions

pembrolizumab 3Pemetrexed 2Cholecalciferol 2vorasidenib 1relacorilant 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1bosutinib 1Trastuzumab 1Sunitinib 1Morphine 1Methadone 1MRX-2843 1Letrozole 1Imatinib Mesylate 1Electrochemotherapy 1Control Groups 1Clomiphene 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 1Azacitidine 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Processes × Imatinib Mesylate × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡